Fly News Breaks for November 7, 2019
Nov 7, 2019 | 08:51 EDT
Raymond James analyst Jayson Bedford raised his price target for DexCom to $189 from $172 following the company's Q3 results. In a research note to investors, Bedford says that while there will always be competitive "noise," Dexcom remains one of the best growth stories in MedTech, supporting his Outperform rating.
News For DXCM From the Last 2 Days
There are no results for your query DXCM